Activation of CAR and non-CAR T cells within the tumor microenvironment following CAR T cell therapy

10.1038/nrclinonc.2017.128

10.1186/s40425-018-0460-5

10.1056/NEJMra1706169

10.1016/j.ymthe.2016.10.020

10.1056/NEJMoa1708566

10.1111/imr.12243

10.1056/NEJMoa1215134

10.1056/NEJMoa1407222

10.1002/ajh.25403

10.1080/10428194.2017.1387905

10.1056/NEJMoa1707447

10.1016/S1470-2045(18)30900-8

[No authors listed]. YESCARTA Prescribing Information. YESCARTA. https://www.yescarta.com/files/yescarta-pi.pdf Accessed May 27, 2020

10.1016/j.beha.2018.07.011

10.1200/JCO.2017.35.15_suppl.3025

Rossi, 2018, Clinical response in ZUMA-1, the pivotal study of axicabtagene ciloleucel (Axi-Cel) in patients with refractory large B cell lymphoma, may be influenced by characteristics of the pretreatment tumor microenvironment (TME), Clin Lymphoma Myeloma Leuk, 18, 10.1016/j.clml.2018.07.213

Rossi, 2019, Abstract CT153: Pretreatment immunoscore and an inflamed tumor microenvironment (TME) are associated with efficacy in patients (Pts) with refractory large B cell lymphoma treated with axicabtagene ciloleucel (Axi-Cel) in ZUMA-1, Cancer Res, 79

10.1016/j.blre.2018.11.002

10.1016/S1470-2045(18)30864-7

Locke, 2017, Abstract CT020: Immune signatures of cytokine release syndrome and neurologic events in a multicenter registrational trial (ZUMA-1) in subjects with refractory diffuse large B cell lymphoma treated with axicabtagene ciloleucel (KTE-C19), Cancer Res, 77

10.1038/s41586-019-1325-x

10.1038/s41586-019-1324-y

10.1038/nri1961

10.1002/ajh.25445

Habermann, 2012, New developments in the management of diffuse large B-cell lymphoma, Hematology, 17 Suppl 1, S93, 10.1179/102453312X13336169156014

10.1016/j.hoc.2019.03.001

10.1634/theoncologist.2018-0028

10.1182/blood-2011-10-384388

10.1038/nature21405

10.1200/JCO.2014.56.2025

10.1038/ni.3682

10.1038/s41591-018-0041-7

10.1038/s41591-018-0036-4

Obstfeld, 2017, Cytokine release syndrome associated with chimeric-antigen receptor T-cell therapy: clinicopathological insights, Blood, 130, 2569, 10.1182/blood-2017-08-802413

10.1182/bloodadvances.2019000600

10.1084/jem.20170580

10.1073/pnas.1715118115

Hashwah, 2019, The IL-6 signaling complex is a critical driver, negative prognostic factor, and therapeutic target in diffuse large B-cell lymphoma, EMBO Mol Med, 11, 10.15252/emmm.201910576

10.1182/bloodadvances.2017012534

10.1158/2159-8290.CD-18-0367

10.1182/blood-2016-09-738245

10.1172/JCI94306

10.1172/JCI125423

10.1158/2159-8290.CD-17-0833

10.1038/s41591-018-0045-3

10.1182/blood-2018-10-881722

10.1016/j.cell.2017.01.016

10.1172/JCI126397

10.1158/1078-0432.CCR-15-1527

10.1126/scitranslmed.aaf8621

10.1002/cbin.10631

10.1016/j.ymeth.2014.08.016

Patel, 2019, The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative, Blood, 134, 2059

10.1182/blood-2017-03-770719

10.1038/s41586-018-0792-9